Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Horizon Therapeutics (NQ: HZNP )

115.61 +0.11 (+0.10%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Horizon Therapeutics

< Previous 1 2 3 4 5 6 7 Next >
Horizon Therapeutics plc to Release Third-Quarter 2022 Financial Results and Host Webcast on Nov. 2, 2022
From Horizon Therapeutics plc
Via Business Wire
New Data Reveal Molecular Drivers of Thyroid Eye Disease (TED) May Remain Activated In Patients with Low Clinical Activity Score (CAS)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Completes Enrollment for Phase 4 Trial of TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Expands Commitment to Education Equity, STEAM Careers and Historically Black Colleges and Universities, Adding Meharry Medical College as Horizon Scholars Partner
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces EB Research Partnership Receives 2022 Horizon Prize, Powered by MIT Solve
From Horizon Therapeutics plc
Via Business Wire
Horizon to Highlight Novel Insights in Gout Care During the American College of Rheumatology Convergence 2022
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Makes Founding Gift to Support the University of Notre Dame’s Patient Advocacy Initiative
From Horizon Therapeutics plc
Via Business Wire
Data from the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection with Methotrexate Published in Arthritis & Rheumatology
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Joins the International Agency for the Prevention of Blindness (IAPB) to Encourage People to #LoveYourEyes this World Sight Day
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces $500 Million Share Repurchase Program
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Ranks Number One on the Fortune Best Workplaces in Biopharma 2022 List
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Named One of PEOPLE’s 100 Companies That Care®
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces Plans to Expand its Development and Manufacturing Facility in Waterford, Ireland
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
From Horizon Therapeutics plc
Via Business Wire
Q32 Bio and Horizon Therapeutics Announce Collaboration in Autoimmune Diseases
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Reports Second-Quarter 2022 Financial Results and Revises Full-Year 2022 Net Sales and Adjusted EBITDA Guidance
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Named a Best Company for Multicultural Women
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces Inaugural #RAREis Global Advocate Grant Recipients
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces Wanda Durant Has Joined Olympian Gail Devers to Raise Awareness of Thyroid Eye Disease Among Graves’ Disease Community
From Horizon Therapeutics plc
Via Business Wire
FDA Approves KRYSTEXXA® (pegloticase) Injection Co-Administered With Methotrexate, Expanding the Labeling to Help More People with Uncontrolled Gout Achieve a Complete Response to Therapy
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Release Second-Quarter 2022 Financial Results and Host Webcast on Aug. 3, 2022
From Horizon Therapeutics plc
Via Business Wire
New Analysis Finds UPLIZNA® (inebilizumab) Effective Among European Populations with Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Submits Regulatory Filing for UPLIZNA® (inebilizumab) in Brazil
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Named One of the Fortune Best Workplaces in Chicago™
From Horizon Therapeutics plc
Via Business Wire
Analysis of Pooled Data from TEPEZZA® (teprotumumab-trbw) Clinical Trials Reinforces Safety Profile in People with Thyroid Eye Disease (TED)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Named a Top Company for Executive Women
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Present at the Goldman Sachs 43rd Annual Global Health Care Conference
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Highlight Data and Education on Thyroid Eye Disease (TED) at the Endocrine Society (ENDO) 2022 Annual Conference
From Horizon Therapeutics plc
Via Business Wire
Data Presented from the MIRROR Randomized Controlled Trial Demonstrate KRYSTEXXA® (pegloticase injection) Plus Methotrexate Resulted in Significant Improvement in Efficacy and Safety (Infusion Reactions) Compared to KRYSTEXXA Monotherapy
From Horizon Therapeutics plc
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.